System analysis based on the T cell exhaustion‑related genes identifies CD38 as a novel therapy target for ovarian cancer.
- Published in:
- Oncology Research, 2023, v. 31, n. 4, p. 591, doi. 10.32604/or.2023.029282
- By:
- Publication type:
- Article
Works matching IS 09650407 AND DT 2023 AND VI 31 AND IP 4
Results: 14
1
2
The SMAD2/miR-4256/HDAC5/p16<sup>INK4a</sup> signaling axis contributes to gastric cancer progression.
- Published in:
- Oncology Research, 2023, v. 31, n. 4, p. 515, doi. 10.32604/or.2023.029101
- By:
- Publication type:
- Article
3
YWHAH activates the HMGA1/PI3K/AKT/mTOR signaling pathway by positively regulating Fra-1 to affect the proliferation of gastric cancer cells.
- Published in:
- Oncology Research, 2023, v. 31, n. 4, p. 615, doi. 10.32604/or.2023.029698
- By:
- Publication type:
- Article
4
Comprehensive analysis of the role of immune-related PANoptosis lncRNA model in renal clear cell carcinoma based on RNA transcriptome and single-cell sequencing.
- Published in:
- Oncology Research, 2023, v. 31, n. 4, p. 543, doi. 10.32604/or.2023.029563
- By:
- Publication type:
- Article
5
mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance.
- Published in:
- Oncology Research, 2023, v. 31, n. 4, p. 495, doi. 10.32604/or.2023.029309
- By:
- Publication type:
- Article
6
Tumor neoantigens: Novel strategies for application of cancer immunotherapy.
- Published in:
- Oncology Research, 2023, v. 31, n. 4, p. 437, doi. 10.32604/or.2023.029924
- By:
- Publication type:
- Article
7
LAMC2 regulates proliferation, migration, and invasion mediated by the Pl3K/AKT/mTOR pathway in oral.
- Published in:
- Oncology Research, 2023, v. 31, n. 4, p. 481, doi. 10.32604/or.2023.029064
- By:
- Publication type:
- Article
8
Underlying mechanisms and clinical potential of circRNAs in glioblastoma.
- Published in:
- Oncology Research, 2023, v. 31, n. 4, p. 449, doi. 10.32604/or.2023.029062
- By:
- Publication type:
- Article
9
Betulinic acid-mediating miRNA-365 inhibited the progression of pancreatic cancer.
- Published in:
- Oncology Research, 2023, v. 31, n. 4, p. 505, doi. 10.32604/or.2023.026959
- By:
- Publication type:
- Article
10
Targeting LncRNA LLNLR-299G3.1 with antisense oligonucleotide inhibits malignancy of esophageal squamous cell carcinoma cells in vitro and in vivo.
- Published in:
- Oncology Research, 2023, v. 31, n. 4, p. 463, doi. 10.32604/or.2023.028791
- By:
- Publication type:
- Article
11
Scaffold proteins of cancer signaling networks: The paradigm of FK506 binding protein 51 (FKBP51) supporting tumor intrinsic properties and immune escape.
- Published in:
- Oncology Research, 2023, v. 31, n. 4, p. 423, doi. 10.32604/or.2023.028392
- By:
- Publication type:
- Article
12
Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients.
- Published in:
- Oncology Research, 2023, v. 31, n. 4, p. 605, doi. 10.32604/or.2023.028321
- By:
- Publication type:
- Article
13
Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials.
- Published in:
- Oncology Research, 2023, v. 31, n. 4, p. 405, doi. 10.32604/or.2023.028310
- By:
- Publication type:
- Article
14
Construction of the panoptosis-related gene model and characterization of tumor microenvironment infiltration in hepatocellular carcinoma.
- Published in:
- Oncology Research, 2023, v. 31, n. 4, p. 569, doi. 10.32604/or.2023.028964
- By:
- Publication type:
- Article